Evaluation of recombinant sporozoite antigen SPAG-1 as a vaccine candidate against Theileria annulata by the use of different delivery systems

N Boulter, D Brown, G Wilkie, S Williamson, E Kirvar, P Knight, E Glass, J Campbell, S Morzaria, V Nene, A Musoke, C d'Oliveira, M J Gubbels, F Jongejan, F. R. Hall

Research output: Contribution to journalArticlepeer-review

Abstract

The major sporozoite surface antigen of Theileria annulata (SPAG-1) is a candidate for inclusion in a subunit vaccine. In this paper we summarize the results of 4 vaccination experiments using recombinant SPAG-1 expressed in different systems and presented in different adjuvants. The antigen has been presented as either a C terminal 108 amino acid peptide (called SR1) expressed as both beta-galactosidase and hepatitis B core antigen fusions or as a full-length form expressed as a GST fusion with an N terminal His6 tag. We used different adjuvants, namely Freund's, saponin, ISCOMs and a proprietary adjuvant supplied by SmithKline Beecham, which we call SKBA. The data point to the conclusion that SPAG-1 can elicit partial protection and is therefore suitable for inclusion in an eventual multicomponent subunit vaccine.
Original languageEnglish
Pages (from-to)A71-7
JournalTropical Medicine and International Health
Volume4
Issue number9
DOIs
Publication statusPublished - Sep 1999

Keywords

  • Animals
  • Antigens, Protozoan
  • Cattle
  • Cattle Diseases
  • Freund's Adjuvant
  • Protozoan Proteins
  • Protozoan Vaccines
  • Recombinant Proteins
  • Theileria annulata
  • Theileriasis

Fingerprint

Dive into the research topics of 'Evaluation of recombinant sporozoite antigen SPAG-1 as a vaccine candidate against Theileria annulata by the use of different delivery systems'. Together they form a unique fingerprint.

Cite this